FDA’s Deceptive Drug Ad Focus Leaves Telehealth Sites Guessing

Loeb & Loeb Regulatory partner Kristen Klesh is featured in Bloomberg Law discussing the U.S. Food and Drug Administration’s (FDA’s) recent focus on deceptive pharmaceutical advertising and the agency’s potential authority to regulate telehealth companies that use social media influencers to promote compounded drugs.

The article explored the challenges the FDA encounters in overseeing influencer marketing and determining how far its authority extends to individuals promoting products online.

“FDA arguably has more jurisdictional authority over brands that are directly responsible for selling the products to consumers,” Kristen told the publication. 

To read the full article, please visit Bloomberg Law’s website.